LoQus23

HuntX Pharma

This biotechnology firm develops oral small-molecule therapeutics targeting axonal transport defects to treat patients with Huntington's disease and other neurodegenerative disorders.

Vico Therapeutics

This company develops antisense oligonucleotide therapies to treat patients with rare genetic neurological disorders, including Huntington's disease and spinocerebellar ataxias.

Trimtech Therapeutics

This biotechnology company develops small molecule drugs that target and degrade toxic protein aggregates to treat neurodegenerative and inflammatory diseases.

Scenic Biotech

This company develops disease-modifying small molecule therapeutics for patients with rare genetic and neurodegenerative disorders using its proprietary genetic modifier discovery platform.

Yumanity Therapeutics

This company develops small molecule drugs to treat neurodegenerative diseases for patients with conditions such as Parkinson's disease and amyotrophic lateral sclerosis.

Ribonaut Therapeutics

Ribonaut Therapeutics develops small molecule drugs that target and degrade disease-causing RNA to treat neurological conditions and movement disorders for human patients.

Switch Therapeutics

This biotechnology company develops conditionally activated genetic medicines to treat central nervous system disorders for patients with neurodegenerative diseases.

NeurOdys Therapeutics

This biotechnology company develops small molecule therapies for patients with neurodegenerative conditions such as Alzheimer's and Parkinson's diseases.